Source comparison
Hexarelin vs IGF-1 LR3: Research Peptide Comparison
Hexarelin Ghrelin receptor agonist; stimulates pulsatile GH release from pituitary somatotrophs 90 minutes (GH pulse duration) 100–200 mcg, 2–3× daily Yes. GHSR-1a downregulation occurs within 7–14 days of continuous use Studies examining natural GH dynamics,
This comparison does not assign a generated winner or score.
- Hexarelin
- Ghrelin receptor agonist; stimulates pulsatile GH release from pituitary somatotrophs
- 90 minutes (GH pulse duration)
- 100–200 mcg, 2–3× daily
- Yes. GHSR-1a downregulation occurs within 7–14 days of continuous use
- Studies examining natural GH dynamics, feedback loop integrity, or interventions modulating endogenous secretion
- Best for preserving physiological axis function; requires intact pituitary; unsuitable for GH-deficient models
- IGF-1 LR3
- Modified IGF-1 analogue with reduced IGFBP binding; direct IGF-1 receptor activation
- 20–30 hours
- 50–150 mcg once daily
- No. IGF-1R remains stable under sustained ligand exposure
- Tissue repair, metabolic studies isolating IGF-1 effects, protocols requiring GH-independent anabolic signalling
- Bypasses GH axis entirely; eliminates upstream variability; risk of hypoglycaemia at high doses due to insulin receptor cross-reactivity
- Endogenous GH (reference)
- Naturally secreted from pituitary in pulsatile pattern; converted to IGF-1 in liver
- 20–30 minutes
- N/A. Physiological baseline
- N/A
- Baseline comparison for secretagogue studies
- Neither peptide replicates natural GH. Hexarelin amplifies pulses; IGF-1 LR3 replaces hepatic IGF-1 synthesis